Added to YB: 2026-09-14
Pitch date: 2026-09-10
CABA [neutral]
Cabaletta Bio, Inc.
Author Info
No bio for this author
Company Info
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Market Cap
$493.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.64
P/E
-1.89
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 2 Section 3 - $CABA
CABA (quick overview): Cabaletta is building a safety-led case for rese-cel, its autologous CD19 CAR-T for autoimmune disease: among more than 90 treated patients, no IEC-HS has been reported, 94% had no CRS or only transient Grade 1 CRS, and approximately 97% had no ICANS. A pivotal scleroderma program is expected by year-end, but the encouraging safety profile still needs to scale into pivotal studies.
Read full article (1 min)